Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · head-neck@1

SRR23036895

—

023e50ad-79a9-5d4d-ba8f-6082fa0395f9

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
  • MYOGENESIS+0.220
  • WNT_BETA_CATENIN_SIGNALING+0.220
  • DNA_REPAIR+0.110
  • ESTROGEN_RESPONSE_EARLY+0.110
  • HEDGEHOG_SIGNALING+0.100
  • ESTROGEN_RESPONSE_LATE+0.090
  • MYC_TARGETS_V2+0.090
  • P53_PATHWAY+0.080
  • BILE_ACID_METABOLISM+0.070

Top 10 suppressed

  • ALLOGRAFT_REJECTION-0.430
  • IL6_JAK_STAT3_SIGNALING-0.390
  • INFLAMMATORY_RESPONSE-0.380
  • TNFA_SIGNALING_VIA_NFKB-0.380
  • INTERFERON_GAMMA_RESPONSE-0.340
  • IL2_STAT5_SIGNALING-0.330
  • TGF_BETA_SIGNALING-0.290
  • APOPTOSIS-0.280
  • ANDROGEN_RESPONSE-0.260
  • MITOTIC_SPINDLE-0.260

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-EW-A424-01A-11R-A24H-07
breast-umap@18
—B0.786
2SRR2016964
head-neck@1
——0.775
3TCGA-E2-A1BD-01A-11R-A12P-07
breast-umap@18
—B0.771
4AUR-AEPZ-TTP1-A-1-1-R-A742-41
breast-umap@18
—B0.766
5TCGA-CV-7414-01A-11R-2081-07
head-neck@1
——0.759
6ea635e80-1225-4f52-a6cf-8f4c20201240
colon-landscapes@1
——0.757
7R208
bladder-landscape@3
——0.746
8ea89121f-2c74-433d-8047-898dc963bf35
colon-landscapes@1
——0.745
9SRR25617832
breast-umap@18
—B0.734
10643bb711-7302-4ba7-bd39-cb0e4d9c2377
colon-landscapes@1
——0.732

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.270Inavolisib— uncovered
MYOGENESIS0.220Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.220Inavolisib— uncovered
DNA_REPAIR0.110Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.110Inavolisib— uncovered
HEDGEHOG_SIGNALING0.100Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.090Idelalisib— uncovered
MYC_TARGETS_V20.090Idelalisib— uncovered
P53_PATHWAY0.080Idelalisib— uncovered
BILE_ACID_METABOLISM0.070Inavolisib— uncovered
APICAL_JUNCTION0.050Inavolisib— uncovered
FATTY_ACID_METABOLISM0.050Inavolisib— uncovered
UV_RESPONSE_DN0.050Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.040Remibrutinib— uncovered
APICAL_SURFACE0.030Temsirolimus— uncovered
ADIPOGENESIS0.020Inavolisib— uncovered
PEROXISOME0.020Idelalisib— uncovered
ANGIOGENESIS0.010Remibrutinib— uncovered
SPERMATOGENESIS0.010Inavolisib— uncovered
UV_RESPONSE_UP0.010Idelalisib— uncovered